| Autor: |
Shiro Ibe, Junko Hattori, Seiichiro Fujisaki, Urara Shigemi, Saeko Fujisaki, Kayoko Shimizu, Kazuyo Nakamura, Takejiro Kazumi, Yoshiyuki Yokomaku, Naoto Mamiya, Motohiro Hamaguchi, Tsuguhiro Kaneda |
| Zdroj: |
AIDS Research & Human Retroviruses; Jan2008, Vol. 24 Issue 1, p7-14, 8p |
| Abstrakt: |
We studied the emergence of drug-resistant human immunodeficiency virus type 1 (HIV-1) with major amino acid mutations in 402 therapy-naive patients at Nagoya Medical Center, Japan, between 1999 and 2006. The mean prevalence of drug-resistant HIV-1 was 6.7 (range, 2.3–10.0; n 27). HIV-1 variants with protease inhibitor (PI)-resistant mutations alone were most frequently found (3.5, n 14), followed by those with nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutations alone (1.7, n 7). Variants with nucleoside reverse transcriptase inhibitor (NRTI)-resistant mutations alone were sporadically found (1.0, n 4). A variant possessing both NRTI- and PI-resistant mutations was detected in one patient (0.2) and a variant possessing both NNRTI- and PI-resistant mutations was identified in another patient (0.2). In addition, another 17 variants (4.2, n 17) with only 215-revertant mutations (T215CDGLS) that can easily reconvert to the nucleoside analogue-associated mutation of T215YF were found. The 402 viruses were phylogenetically analyzed, revealing three independent clusters comprising PI-resistant variants with the M46I or L90M mutation, NNRTI-resistant variants with the K103N mutation, and 215-revertant variants. The PI-resistant and 215-revertant strains have been spreading since 2000, and the NNRTI-resistant strain has started spreading since 2003. The nature of the epidemic and information for successfully blocking the spread of drug-resistant HIV-1 were clarified in this study. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
